Paulin Mathieu Victor, Schermerhorn Thomas, Unniappan Suraj, Snead Elisabeth C R
Department of Small Animal Clinical Sciences, Western College of Veterinary Medicine, University of Saskatchewan, Saskatoon, SK, Canada.
Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS, United States.
Front Vet Sci. 2025 Mar 14;12:1528008. doi: 10.3389/fvets.2025.1528008. eCollection 2025.
Although arginine vasopressin (AVP) deficiency, AVP resistance, and primary polydipsia are important causes of polyuria and polydipsia (PUPD), measurement of AVP has never been implemented as a routine diagnostic test for patient care in either human or veterinary medicine, due to significant challenges with the methodologic reliability of laboratory assays for measuring AVP. Responses to a modified water deprivation test and/or a desmopressin acetate trial have been used as indirect markers of AVP deficiency or resistance. However, interpretations of these tests can be especially challenging in cases of partial AVP deficiency or resistance. Over the past decade, plasma copeptin (CoP), a glycopeptide comprising the C-terminal part of the AVP preprohormone, has mostly replaced AVP measurement in humans. When combined with CoP-based stimulation tests, such as hypertonic saline and arginine stimulation tests, plasma CoP measurement offers excellent diagnostic accuracy for the diagnosis and differentiation of cases of central diabetes insipidus (DI), nephrogenic DI, and primary polydipsia in humans. In dogs, CoP has recently been measured in saliva and serum using canine or human enzyme-linked immunosorbent assays. This review will provide an update on the physiologic regulation of AVP production and secretion, the limitations of its measurement in human and veterinary medicine, as well as a summary of the indications and performance of CoP measurement in human and veterinary medicine to date. This is with a purpose to encourage validation and implementation of CoP measurement in veterinary medicine.
尽管精氨酸加压素(AVP)缺乏、AVP抵抗和原发性烦渴是多尿和烦渴(PUPD)的重要原因,但由于测量AVP的实验室检测方法在方法学可靠性方面存在重大挑战,在人类或兽医学中,AVP测量从未作为患者护理的常规诊断测试实施。对改良禁水试验和/或醋酸去氨加压素试验的反应已被用作AVP缺乏或抵抗的间接标志物。然而,在部分AVP缺乏或抵抗的情况下,这些测试的解释可能特别具有挑战性。在过去十年中,血浆 copeptin(CoP),一种由AVP前激素原的C末端部分组成的糖肽,在人类中已基本取代了AVP测量。当与基于CoP的刺激试验(如高渗盐水和精氨酸刺激试验)相结合时,血浆CoP测量为人类中枢性尿崩症(DI)、肾性DI和原发性烦渴的诊断和鉴别提供了出色的诊断准确性。在犬类中,最近已使用犬类或人类酶联免疫吸附测定法在唾液和血清中测量CoP。本综述将提供关于AVP产生和分泌的生理调节的最新信息、其在人类和兽医学中测量的局限性,以及迄今为止CoP测量在人类和兽医学中的适应症和性能总结。目的是鼓励在兽医学中验证和实施CoP测量。